From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Adverse Event
Grade 1
Grade 2
Grade 3–4
Injection Site Pain
10
0
Headache
6
Fatigue
1
Anorexia
Fever
2
Nausea
3
Rash
Infection
Respiratory
Hepatic
Thrombocytopenia
Anemia